<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00125853</url>
  </required_header>
  <id_info>
    <org_study_id>NPSW02</org_study_id>
    <nct_id>NCT00125853</nct_id>
  </id_info>
  <brief_title>The Effect of Nebivolol on Insulin Sensitivity</brief_title>
  <official_title>A Trial to Compare the Effects of Nebivolol Versus Atenolol on Various Cardiovascular Measurements Including Insulin Sensitivity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Foundation for Circulatory Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to conduct a randomised trial to compare the insulin
      sensitivity, 24 hour blood pressure profile, and tolerability of nebivolol plus a
      thiazide-like diuretic versus atenolol plus a thiazide-like diuretic.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Retrospective studies of treated hypertensive cohorts have strongly implicated beta blocker
      therapy as increasing the risk of developing new-onset diabetes. This has led to the latest
      British Hypertension Society guidelines advising caution when using beta blockers
      particularly in combination with thiazide-like diuretics. However the National Institute of
      Clinical Excellence recommends beta-blocker + thiazide combinations as the treatment of
      choice in patients who are not at increased risk of developing diabetes. Nebivolol is a newer
      class of beta blocker. Some studies in diabetic hypertensive patients have suggested that
      nebivolol does not impair insulin sensitivity. The aim of this study is to compare the effect
      on insulin sensitivity of nebivolol versus atenolol, both in combination with a thiazide-like
      diuretic, in a group of non-diabetic hypertensive patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in insulin sensitivity</measure>
    <time_frame>Between baseline and 20 weeks after enrollment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in 24 hour blood pressure</measure>
    <time_frame>Between baseline and 20 weeks after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in cholesterol</measure>
    <time_frame>Between baseline and 20 weeks after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in HbA1c</measure>
    <time_frame>Between baseline and 20 weeks after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in body weight</measure>
    <time_frame>Between baseline and 20 weeks after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Forced Expiratory Volume 1 (FEV1)</measure>
    <time_frame>Between baseline and 20 weeks after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in wellbeing</measure>
    <time_frame>Between baseline and 20 weeks after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in cerebral blood flow</measure>
    <time_frame>Between baseline and 20 weeks after enrollment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>atenolol 25mg daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>atenolol 25mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nebivolol 2.5mg daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>nebivolol 2.5mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebivolol</intervention_name>
    <description>Nebivolol 25mg daily</description>
    <arm_group_label>nebivolol 2.5mg daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atenolol</intervention_name>
    <description>Atenolol 25mg daily</description>
    <arm_group_label>atenolol 25mg daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females of any age

          -  Blood pressure that meets any of the three following criteria:

               -  Systolic blood pressure (SBP) &lt;= 160 and diastolic blood pressure (DBP) &lt;= 90 on
                  one antihypertensive drug; OR

               -  SBP &lt;= 140 and DBP &lt;= 85 on two antihypertensive drugs; OR

               -  SBP 140-170 and DBP 90-100 on no antihypertensive drugs.

        Exclusion Criteria:

          -  Compelling indication for treatment with a beta blocker

          -  Contraindication to, or previous history of, major intolerance to treatment with a
             beta blocker or thiazide-like diuretic

          -  Any condition that will interfere with the treatment or the patient's ability to
             complete the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil R Poulter</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Imperial College London</name>
      <address>
        <city>Paddington</city>
        <state>London</state>
        <zip>W2 1PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2005</study_first_submitted>
  <study_first_submitted_qc>July 29, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2005</study_first_posted>
  <last_update_submitted>April 7, 2014</last_update_submitted>
  <last_update_submitted_qc>April 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>blood pressure</keyword>
  <keyword>insulin sensitivity</keyword>
  <keyword>beta blockers</keyword>
  <keyword>randomised double blind crossover trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Nebivolol</mesh_term>
    <mesh_term>Atenolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

